Published May 1, 2011 | Version v1
Journal article

A study of the enhanced sensitizing capacity of a contact allergen in lipid vesicle formulations

  • 1. Department of Chemistry, University of Gothenburg, SE-412 96, Gothenburg (Sweden)
  • 2. Department of Dermatology, Odense University Hospital, University of Southern Denmark, DK-5000, Odense (Denmark)
  • 3. Department of Physics, University of Gothenburg, SE-412 96, Gothenburg (Sweden)

Description

The growing focus on nanotechnology and the increased use of nano-sized structures, e.g. vesicles, in topical formulations has led to safety concerns. We have investigated the sensitizing capacity and penetration properties of a fluorescent model compound, rhodamine B isothiocyanate (RBITC), when administered in micro- and nano-scale vesicle formulations. The sensitizing capacity of RBITC was studied using the murine local lymph node assay (LLNA) and the skin penetration properties were compared using diffusion cells in combination with two-photon microscopy (TPM). The lymph node cell proliferation, an indicator of a compounds sensitizing capacity, increased when RBITC was applied in lipid vesicles as compared to an ethanol:water (Et:W) solution. Micro-scale vesicles showed a slightly higher cell proliferative response compared to nano-scale vesicles. TPM imaging revealed that the vesicle formulations improved the skin penetration of RBITC compared to the Et:W solution. A strong fluorescent region in the stratum corneum and upper epidermis implies elevated association of RBITC to these skin layers when formulated in lipid vesicles. In conclusion, the results indicate that there could be an elevated risk of sensitization when haptens are delivered in vehicles containing lipid vesicles. Although the size of the vesicles seems to be of minor importance, further studies are needed before a more generalized conclusion can be drawn. It is likely that the enhanced sensitizing capacity is a consequence of the improved penetration and increased formation of hapten-protein complexes in epidermis when RBITC is delivered in ethosomal formulations. - Graphical Abstract: Display Omitted

Availability note (English)

Available from http://dx.doi.org/10.1016/j.taap.2011.02.010

Additional details

Identifiers

DOI
10.1016/j.taap.2011.02.010;
PII
S0041-008X(11)00056-1;

Publishing Information

Journal Title
Toxicology and Applied Pharmacology
Journal Volume
252
Journal Issue
3
Journal Page Range
p. 221-227
ISSN
0041-008X
CODEN
TXAPA9

Optional Information

Copyright
Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.